A neutral, evidence-rated side-by-side of Cardarine (GW-501516, PPARδ agonist) and Stenabolic (SR-9009, REV-ERB agonist). Figures are typical reference values, not recommendations.
| Cardarine (GW-501516, PPARδ agonist) | Stenabolic (SR-9009, REV-ERB agonist) | |
|---|---|---|
| Type | SARM | SARM |
| Evidence level | Limited | Limited |
| Primary class | Non-steroidal | Non-steroidal |
| Half-life | ~20-24 hours | ~4 hours (short; poor oral bioavailability) |
| Typical dose | 10–20 mg/day | 20–30 mg/day |
| Documented effects | 3 | 3 |
| Documented side effects | 2 | 2 |
Cardarine (GW-501516) is not a SARM but a PPARδ agonist, developed for dyslipidaemia and studied for its effects on fat metabolism and endurance. Development was halted after long-term rodent studies showed dose-dependent cancers in multiple organs. This carcinogenicity signal is the dominant safety concern; whether it translates to humans is disputed and unresolved.
Full Cardarine (GW-501516, PPARδ agonist) page →Stenabolic (SR-9009) is not a SARM but a REV-ERB agonist studied in mice for effects on circadian metabolism, endurance and fat loss. It has essentially no human data and, critically, very poor oral bioavailability, casting doubt on whether oral use produces meaningful effects. It does not act on the androgen receptor, so no steroid profile applies.
Full Stenabolic (SR-9009, REV-ERB agonist) page →